Novo Nordisk receives subpoena from US Attorney

Novo Nordisk receives subpoena from US Attorney

Bagsværd, Denmark 24 October 2014 - Novo Nordisk today announced that it has been served with a subpoena by the office of the US Attorney for the District of Massachusetts requesting documents regarding potential manufacturing issues within certain production units located in Kalundborg, Denmark.

Novo Nordisk is cooperating fully with the US Attorney in this investigation. At this time, Novo Nordisk cannot determine or predict the outcome of this matter or assess the consequences thereof. In addition, the company cannot predict how long the investigation will take or when it will be able to provide additional information.

Novo Nordisk takes patient safety and product quality very seriously and is confident in the safety of its products.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries.

For more information, visit novonordisk.com.

Further information

Media:

Mike Rulis +45 3079 3573 [email protected]

Investors:

Kasper Roseeuw Poulsen +45 3079 4303 [email protected]

Jannick Lindegaard Denholt +45 3079 8519 [email protected]

Daniel Bohsen +45 3079 6376 [email protected]

Frank Daniel Mersebach (US) +1 609 235 8567 [email protected]

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.